News for Rhythm Pharmaceuticals, Inc. (RYTM)

Strengths: Innovative therapies and strong market presence in rare disease treatment.Weaknesses: Limited operating history and ongoing net losses.Opportunities

Significant Transaction by PERCEPTIVE ADVISORS LLC (Trades, Portfolio) On January 8, 2025, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a noteworthy tra

Cash and Cash Equivalents: $320.6 million at the end of 2024.Revenue: $41.8 million in Q4 2024; $130.1 million for the full year 2024.Cost of Sales: $3.8 milli

Feb 26, 2025 / 01:00PM GMTOperator Good day and welcome to Rhythm Pharmaceuticals fourth quarter and fiscal year 2024 earnings conference call. [Operator Instru

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ETCompany ParticipantsDavid Connolly – Investor...

The following slide deck was published by Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -4.35% and 2.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

-- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from global Pha

Significant Acquisition by PERCEPTIVE ADVISORS LLC (Trades, Portfolio) On February 13, 2025, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a notable addition

On February 19, 2025, Perceptive Advisors LLC made a significant move by acquiring an additional 5,028,033 shares of Solid Biosciences Inc (SLDB). This transact

On February 19, 2025, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) made a significant move by acquiring an additional 3,659,374 shares of Solid Biosciences I

On December 31, 2024, RA Capital Management, L.P. made a significant move by acquiring an additional 2,768,289 shares of Verona Pharma PLC. This transaction inc

Significant Transaction in Unicycive Therapeutics Inc. On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a noteworthy transaction b

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) made a significant move by acquiring an additional 2,811,454 shares of NewAmsterdam Pharma

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a significant transaction involving Recursion Pharmaceuticals Inc (RXRX). The fir

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 1,531,713 shares of Protara T

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,181,818 shares of EyePoint Pharmaceutical

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a significant reduction in its holdings of Evolent Health Inc (EVH). The firm dec

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio), a prominent investment firm, expanded its stake in Dianthus Therapeutics Inc (DNTH) by ac